Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19
Keywords:
Renin-angiotensin system, COVID-19, Angiotensin-converting enzymeAbstract
COVID-19 is a new disease caused by the Sars-CoV-2 virus and the vast majority of patients have symptoms similar to a flu-like syndrome. A small portion of those infected ends up being hospitalized and may develop with the most severe presentation of the disease. Data from Chinese series report that hypertension appears to be a condition that imposes a greater risk of unfavorable evolution of patients. Some studies have reported that Sars-CoV-2 uses the angiotensin-converting enzyme to access its target cells. There are theories that differ about the protective or harmful role that drugs that act in the renin angiotensin aldosterone system in these patients. A British study suggests that patients using angiotensin-converting enzyme inhibitors had a lower incidence of severe forms of the disease. Another study carried out a retrospective and multicenter analysis showing that mortality was lower in the group that had used the drugs when compared to the other group (3,7 vs. 9,8%; p=0,01). The various hypotheses raised through pathophysiology are not yet able to really predict the best course of action for patients using drugs that act on the renin angiotensin system. Thus, a randomized study becomes important to try to answer definitively and with a high degree of reliability to this question.
Downloads
References
- Zhou P, Yang X-L, Wang X-G, Hu Ben, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270–273.
- Guan W-J, Ni Z-Y, Hu Y, Liang WH, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; doi: 10.1056/NEJMoa2002032.
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; doi:10.1016/S2213-2600(20)30079-5.
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 1818(2): 271-280.
- Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020; 367(6485):1444-1448.
- Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020; doi: 10.1002/jmv.25726
- Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17(11):3067–75
- Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15(5): 327–47.
- Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020 Jan; 94(7). doi: 10.1128/JVI.00127-20
- Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular Research. 2020; 116(6):1097-1100.
- Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus- induced lung injury. Nature Medicine. 2005; 11(8):875-879.
- Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. 2005; 436(7047):112-116
- Zheng YY, Ma YT, Zhang JY and Xie X. COVID-19 and the cardiovascular system. Nature Ver Cardiol. 2020; 17(5):259-260.
- Vincent JL, Taccone FS. Understanding pathways to death in patients with COVID-19. Lancet Respir Med. 2020 Apr 6. pii: S2213-2600(20)30165-X. doi: 10.1016/S2213-2600(20)30165-X.
- Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; published online Feb 24. https://doi.org/10.1016/S22132600(20)30079-5.
- Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. NEJM. 2020; 382(17): 1653-1659.
- Bean DM, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, Roguski L, Noor K, Shek A, O`Gallagher K, Zakeri R, Shah AM, Teo JTH, Dobson RJB. Treatment with ACE_inhibitors is associated with less severe disease with SARS-covid-19 infection ina multi-site UK acute Hospital Trust. BMJ.2020 https://doi.org/10.1101/2020.04.07.20056788
- Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality patients with hypertension hospitalized with COVID-19. Circ Res. 2020 doi: 10.1161/CIRCRESAHA.120.317134.
- Li J, Wang X, Chen J, Zhang H Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus Disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020
- Danser AHJ, Epstein M, Batlle D. Renin- Angiotensin System Blockers and the COVID-19 Pandemic. Hypertension. 2020 doi: 10.1161/HYPERTENSIONAHA.120.15082
